Cancer & Oncology CME/CE Online Courses

Cancer Therapy CME/CE Courses

Cancer Therapy CME/CE Courses

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

Targeted Treatments for Urothelial Cancer

Targeted Treatments for Urothelial Cancer

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), AANP Contact Hour(s)
This activity will help advanced practitioners who treat patients with UC to know how to select and sequence these treatments.
Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

AMA PRA Category 1 Credit(s)TM
The advent of poly-(ADP ribose)-polymerase (PARP) inhibitors for a variety of malignancies has led to the evaluation of their use in patients with metastatic castrate resistant prostate cancer (mCRPC), and has the potential to shift treatment paradigms for these patients.
1,800 Seconds™ in The Expanding Role of PARP Inhibitors in Ovarian Cancer

1,800 Seconds™ in The Expanding Role of PARP Inhibitors in Ovarian Cancer | myCME

AMA PRA Category 1 Credit(s)TM
A 30-minute video-based online module designed to provide an overview of current evidence on the expanding role of PARP inhibitors in the treatment of ovarian cancer. Dr. Kathleen Moore presents a patient case to provide context for a discussion of emerging data, ongoing clinical trials, and evidence-based strategies to support appropriate selection of patients for treatment with PARP inhibitors.
Managing Immune-Related Adverse Events in the ED With the Advent of Combination Therapies

Managing Immune-Related Adverse Events in the ED | myCME

AMA PRA Category 1 Credit(s)TM
This 1.0-hour, CME-certified program, presented by Drs Christopher J. Coyne and Jayne Viets-Upchurch, will review the fundamentals of ICIs as used for cancer treatment, including standard-of-care regimens and the mechanisms of action for these agents. It will also highlight guideline-recommended approaches to recognizing and treating irAEs associated with ICI monotherapies and combination regimens in the ED setting.
Disparities and Improving the Care of Advanced HCC in the Hispanic Community

Disparities and Improving the Care of Advanced HCC in the Hispanic Community | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s)
Significant race and ethnicity-specific disparities in HCC care account in many respects for the increased incidence—approximately 36%—of HCC among Hispanics, who are more likely to present late and less likely to receive any HCC-directed treatment. However, improved screening and surveillance guidelines and greater understanding of the pathophysiology and molecular pathways in HCC has led to the emergence of targeted treatment.
A 35-year-old Woman with Worsening Pain and Swelling in the Knee

A 35-year-old Woman with Worsening Pain and Swelling in the Knee | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), CE for Pharmacists
The current standard of care for localized tenosynovial giant cell tumors (TGCT) is surgical resection; however, diffuse disease often has more extensive involvement and a lower likelihood of a successful cure with surgery, higher risk of recurrence, and substantial morbidity and lower quality of life. These issues come to light for a 35-year-old woman who presents to her primary care physician with worsening pain and swelling in the knee, and is later diagnosed with, and treated for TGCT.

Click for More Oncology Courses

Next hm-section-front in CME